Article
CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non-Small Cell Lung Cancer.
Cancer research - 15 Dec 2023
Prahallad Anirudh, Weiss Andreas, Voshol Hans, Kerr Grainne, Sprouffske Kathleen, Yuan Tina, Ruddy David, Meistertzheim Morgane, Kazic-Legueux Malika, Kottarathil Tina, Piquet Michelle, Cao Yichen, Martinuzzi-Duboc Laetitia, Buhles Alexandra, Adler Flavia, Mannino Salvatore, Tordella Luca, Sansregret Laurent, Maira Sauveur-Michel, Graus Porta Diana, Fedele Carmine, Brachmann Saskia M
Abstract excerpt
Although KRASG12C inhibitors show clinical activity in patients with KRAS G12C mutated non-small cell lung cancer (NSCLC) and other solid tumor malignancies, response is limited by multiple mechanisms of resistance. The KRASG12C inhibitor JDQ443 shows enhanced preclinical antitumor activity combined with the SHP2 inhibitor TNO155, and the combination is currently under clinical evaluation. To identify rational...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.